Ocugen, Inc. — Director's Dealing 2018

Aug 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2018-07-31

Reporting Person: Kelley Lynne E (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-31	Employee Stock Option (Right to Buy)	$2.21	A	200000	Acquired	2028-07-30	Common Stock (200000)	Direct

Footnotes

F1: This option vests over four (4) years of service following August 6, 2018, with twenty-five percent (25%) vesting upon completion of one (1) year of continuous service and the balance vesting in thirty-six (36) equal monthly installments thereafter.